Mirjam T Epping
Overview
Explore the profile of Mirjam T Epping including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lunardi A, Ala U, Epping M, Salmena L, Clohessy J, Webster K, et al.
Nat Genet
. 2020 Sep;
52(10):1132.
PMID: 32884149
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
2.
Gonzalez-Billalabeitia E, Seitzer N, Song S, Song M, Patnaik A, Liu X, et al.
Cancer Discov
. 2014 May;
4(8):896-904.
PMID: 24866151
Unlabelled: Prostate cancer is the most prevalent cancer in males, and treatment options are limited for advanced forms of the disease. Loss of the PTEN and TP53 tumor suppressor genes...
3.
Lunardi A, Ala U, Epping M, Salmena L, Clohessy J, Webster K, et al.
Nat Genet
. 2013 Jun;
45(7):747-55.
PMID: 23727860
Here we report an integrated analysis that leverages data from treatment of genetic mouse models of prostate cancer along with clinical data from patients to elucidate new mechanisms of castration...
4.
Dummer R, Beyer M, Hymes K, Epping M, Bernards R, Steinhoff M, et al.
Leuk Lymphoma
. 2012 Jan;
53(8):1501-8.
PMID: 22239668
The retinoid X receptor (RXR)-agonist bexarotene and the histone deacetylase inhibitor (HDACI) vorinostat are each established monotherapies for cutaneous T-cell lymphomas (CTCLs). We investigated the combination of HDACI and retinoic...
5.
Epping M, Meijer L, Krijgsman O, Bos J, Pandolfi P, Bernards R
Nat Cell Biol
. 2010 Dec;
13(1):102-8.
PMID: 21170034
We have previously reported a gene expression signature that is a powerful predictor of poor clinical outcome in breast cancer. Among the seventy genes in this expression profile is a...
6.
Epping M, Meijer L, Bos J, Bernards R
Mol Cancer Res
. 2009 Oct;
7(11):1861-70.
PMID: 19843631
To identify potential biomarkers of therapy response, we have previously done a large-scale gain-of-function genetic screen to identify genes whose expression confers resistance to histone deacetylase inhibitors (HDACI). This genetic...
7.
Oehler V, Guthrie K, Cummings C, Sabo K, Wood B, Gooley T, et al.
Blood
. 2009 Jul;
114(15):3299-308.
PMID: 19625708
The preferentially expressed antigen in melanoma (PRAME) is expressed in several hematologic malignancies, but either is not expressed or is expressed at only low levels in normal hematopoietic cells, making...
8.
Huang S, Laoukili J, Epping M, Koster J, Holzel M, Westerman B, et al.
Cancer Cell
. 2009 Apr;
15(4):328-40.
PMID: 19345331
Retinoids play key roles in differentiation, growth arrest, and apoptosis and are increasingly being used in the clinic for the treatment of a variety of cancers, including neuroblastoma. Here, using...
9.
Fotheringham S, Epping M, Stimson L, Khan O, Wood V, Pezzella F, et al.
Cancer Cell
. 2008 Dec;
15(1):57-66.
PMID: 19111881
Aberrant acetylation has been strongly linked to tumorigenesis, and the modulation of acetylation through targeting histone deacetylases (HDACs) is gathering increasing pace as a viable therapeutic strategy. A genome-wide loss-of-function...
10.
Epping M, Bernards R
Int J Biochem Cell Biol
. 2008 Sep;
41(1):16-20.
PMID: 18765293
Histone deacetylase inhibitors comprise a variety of natural and synthetic compounds, which have in common that they inhibit enzymes that mediate the removal of acetyl groups from a range of...